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ABSTRACT - ENGLISH 
 
Summary: PE and HIV dualism in pregnant HAART women are yet to be investigated. 
Furthermore, the effect on VEGFR-3 and subsequent downstream influence on angiogenesis is 
poorly understood. Therefore, this investigation evaluates the immuno-expression of VEGFR-3 
in placental conducting and exchange villi from normotensive, preeclamptic and HIV+ African 
women, using morphometric image analysis. 
Study design: This is a prospective study utilizing retrospectively collected, paraffin wax-
embedded, placental samples (n=90) that were immuno-stained for VEGFR-3. The study 
population consisted of normotensive (n=30) and pre-eclamptic (n=60) groups which were further 
stratified on the basis of HIV status (negative - and positive +), and early and late onset 
preeclampsia (EOPE and LOPE respectively). The final groups were as follows; N- (n=15), N+ 
(n=15), EOPE- (n=15), EOPE+ (n=15), LOPE- (n=15) and LOPE+ (n=15). Brightfield 
microscopy and morphometric image analysis of VEGFR-3 immuno-expression within 
conducting and exchange placental villi was performed. 
Results: HIV status analysis did not demonstrate a significant difference in VEGFR-3 
immunostaining for both villous types. The N vs. PE comparative analysis showed a 
downregulated immuno-expression of VEGFR-3 in both conducting (p = 0.0107) and exchange 
(p < 0.0001) villi. Results from analysis of pregnancy subtypes showed a significant difference in 
VEGFR-3 expression between N vs. EOPE regardless of villous type.  
Conclusion: This study demonstrates that HIV infection does not significantly alter VEGFR-3 
placental immuno-expression in pregnant women receiving HAART irrespective of pregnancy 
type. Furthermore, VEGFR-3 immuno-expression was dysregulated in EOPE women, 
irrespective of HIV status. These novel findings emphasize severe down-regulation of VEGFR-3 
in preeclamptic women, and provide compelling evidence for a future investigation into placental 
angiogenic and lymphangiogenic regulation in the early onset of PE.    
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ABSTRACT – ISIZULU 
 
Isifinyezo: Inhlanganyela yePE neHIV kwabesifazane abakhulelwe abemukela iHAART 
kusamele kuphenywe. Ngakho-ke, lolu phenyo luhlola ukubonakaliswa kwe-VEGFR-3 
kwiplacental ekuqhubeni nasekushintshaniseni i-villi kusuka ku-normotensive, preeclamptic ne-
HIV+ kwabesifazane abansundu, kusetshenziswa ukuhlaziywa kwezithombe. 
Umklamo wokutadisha: Lokhu kucwaninga okungenzeka kusetshenziswa amasampula eplacental 
aqoqiwe, afakwe kwi-paraffin wax (n=90) abegcinelwe i-immuno-stain for VEGFR-3. Inani 
labantu abacwaningwayo liqukethe amaqembu: i-Normotensive (n=30) kanye ne-pre-eclamptic 
(n = 60) abephinde ahlukaniswa ngesisekelo sesimo se-HIV (abangenayo i-HIV Kanye nabanayo 
i-HIV+), kanye nabaqalwa yi-preeclampsia nalabo abakhombisa i-preeclamsia emva kwesikhathi 
eside (i-EOPE ne-LOPE) ngokulandelana. ). Amaqembu esewonke ngokulandelayo; N- (n=15), 
N+ (n=15), EOPE- (n=15), EOPE+ (n=15), LOPE- (n=15) no-LOPE+ (n=15). IBrightfield 
microscopy nokuhlaziywa kwezithombe imorphometric yeVEGFR-3 nokuziveza kwayo 
ngokuqhuba nokushintshaniswa kweplacental villie kwenziwa. 
Imiphumela: Ukuhlaziywa kwesimo seHIV akuvezanga umehluko omkhulu kwiVEGFR-3 
immuno-staining kuzo zombili izinhlobo zeVillous. Ukuhlaziywa kokuqhathaniswa kwe-N vs. 
PE kukhombise ukubonakaliswa okuphansi kwe-immuno-expression kwe-VEGFR-3 kokubili 
kuqhuba (p = 0.0107) kanye nokushintshaniswa (p < 0.0001) villi. Imiphumela yokuhlaziywa 
kwezinhlobo ezahlukene zokukhulelwa zikhombise omkhulu umehluko ekubonisweni 
kweVEGFR-3 phakathi kwe N iqhathaniswa neEOPE kungakhathaleleki uhlobo lwevillous. 
Isiphetho: Lomkamo ukhombisa ukuthi ukutheleleka nge HIV akunawo umthelela omkhulu 
ekuvimbeni iVEGFR-3 immuno-expression kwabesifazane abakhulelwe abemukela iHAART 
kungakhathalaleki uhlobo lokukhulelwa. Ngaphezu kwalokho, iVEGFR-3 immuno-expression 
kwabesifazane abaneEOPE ayisebenzanga, kungakhathaleki isimo sabo seHIV. Okutholakale 
emibhalweni lugcozelela ngokukhulu ukwehla kwezinga kweVEGFR-3 kwabesifazane aba-
preeclamptic, futhi kunikeza ubufakazi obuqanda ikhanda obungasetshenziswa kucwaningo 
oluzayo kweplacental angiogenic nelymphangiogenic regulation kulabo abaqedwa yiPE. 
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BACKGROUND AND LITERATURE REVIEW 
 
Spiritual scriptures emphasize the importance of women and how they should be revered; 
however, women are no longer treated with the highest respect and honour, and have become 
plagued with sorrow and disease (Baba, 2005). It is one of many duties of scientists and 
spiritualists, to unite and piece together a puzzle of varying knowledge for the healing and 
upliftment of the mothers of this land (Baba, 2005). 
 
1.1 Maternal mortality in South Africa 
A staggering 7.97 million South Africans are infected with the human immunodeficiency virus 
(StatsSA, 2019). Females in their child-bearing years (15-49 years) comprise an estimated 22.47% 
(StatsSA, 2019). Despite major advances in antiretroviral therapy (ART), a vertical transmission 
of <10% still exists (UNAIDS, 2018).  
Pregnancy is also complicated by hypertensive disorders of pregnancy (HDP). Low and middle 
income countries, e.g. South Africa, have experienced an alarming 14% increase in maternal 
mortality between 2011-2016, due to HDPs (NCCEMD, 2018; Nathan et al., 2018). The most 
pronounced contributor is preeclampsia (PE), which accounts for more than 83% of deaths 
reported (NCCEMD, 2018; Moodley et al., 2019).   
 
1.2 The Human Immunodeficiency Virus (HIV) in pregnancy 
In vertical transmission of HIV, the virus infected cells cross the uteroplacental mucosa and 
permeate the trophoblast epithelia (Figure 1.1) where they may remain undetected by surrounding 
maternal immune defense cells (Milligan et al., 2018; Ander et al., 2019). The high mutation rate 
of HIV causes CD4+ and CD8+ T cell and B cell exhaustion (Bussmann et al., 2010; Moir and 
Fauci, 2009). T cell availability and functioning is also dysregulated during HIV infection (Shive 
et al., 2016; Saito et al., 2018), leading to the suggestion that this anomaly decreases maternal 
tolerance of the fetus (Altfeld and Bunders, 2016). Furthermore nullification of natural killer cell 
function, impedes their ability to contribute towards optimal immune defense and placental artery 
formation (Wang, 2010). Nonetheless, the physiological maternal-fetal equilibrium is altered 
(Wang, 2010).  
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Figure 1.1: Depiction of the site of implantation which also forms the maternal-fetal interface. Immediately 
surrounding the blastocyst are the trophoblastic layers of cells which are differentiated into a 
cytotrophoblast and syncytiotrophoblast layers. Beyond the syncytiotrophoblast, in the decidua, are 
maternal immune defensive cells. Adapted from (Mor et al., 2017).  
 
South Africa is recognized as having the highest rollout of antiretroviral (ARV) therapy in the 
world (Naicker et al., 2019). The usage of ARVs reduce the rate of vertical transmission and 
prevent progression of HIV infection to acquired immunodeficiency syndrome (Roberts and 
Escudero, 2012).  
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1.3 Preeclampsia  
1.3.1 Clinical characteristics 
PE is a medical disorder developing at/after 20 weeks gestation (Brown et al., 2018), and is caused 
by the presence of the placenta (Roberts and Escudero, 2012). PE women present with a new 
onset of hypertension (≥ 140/90 mmHg) and may have associated proteinuria (Kalumba et al., 
2013; Brown et al., 2018). However, not all women present with these clinical manifestations 
(Douglas and Redman, 1994; Knight, 2007; Morikawa et al., 2012; Ohno, 2018).  
PE may be sub-classified as an early onset (EOPE; < 34weeks gestation) or late onset (LOPE > 
34 weeks gestation, near term) sub-types (James et al., 2010; Staff and Redman, 2018). Presently, 
emergency delivery and subsequent expulsion of the placenta is the primary method of restoring 
maternal and neonatal health (Jeyabalan, 2013; Rana et al., 2019).  
 
1.3.2 Etiopathogenesis 
1.3.2.1 The placenta: Anatomical location and function 
The placenta is a highly vascular organ that is anatomically located (Figure 1.2) to the anterior or 
posterior wall of the uterus (Fidan et al., 2017). Centrally arising from the placenta and connecting 
to the fetus is the umbilical cord. Physiologically, the placenta functions in exchange of gases, 
waste excretion, hormone secretion, maintenance of homeostasis, etc., between the maternal and 
fetal circulation (Young et al., 2014).  
 
Figure 1.2: Simple illustration of the placenta, fetus and umbilical cord in utero. The placenta is seen as a 
disk or pan-shaped organ located to the posterior uterine wall. Adapted from Biorender.com. 
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1.3.2.2 Synopsis of the genesis of the placenta 
At the time of implantation, trophoblast cells immediately surrounding the blastocyst begin to 
differentiate and thereafter mediate blastocyst implantation into the decidua of the endometrium 
(Kliman, 1999). Trophoblasts proliferate to form an inner cytotrophoblast and outer 
syncytiotrophoblast (STB) (Baergen, 2011) layer of cells. Trophoblast cells actively invade the 
decidua (James et al., 2010), penetrate the endometrial spiral arteries (Kliman, 1999) and remodel 
both the decidual and myometrial arteries in a set time sequence (Naicker et al., 2019).  
Fetal circulation is established three weeks after fertilization and comprises chorionic villi (Figure 
1.3).  Conducting villi (stem) branch into exchange villi viz., intermediate (mature and immature) 
and terminal villi (Benirschke and Kaufmann, 1942; Slator et al., 2018). These finely branched 
structures are important for exchange of gases, nutrients and waste between the maternal and fetal 
circulations (Kliman, 1999). At four weeks gestation, a mature placenta is established (Kliman, 
1999).  
 
 
Figure 1.3: Simple, labelled illustration of placental anatomy. Adapted from Biorender.com.  
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1.3.2.3 Two stage theory of PE 
The etiopathogenesis of PE is not completely understood, but it has been well established that it 
begins in the placenta and consists of two stages (Figure 1.4). Vasculogenesis is the de novo 
synthesis of the fetal vascular system, whilst angiogenesis is pertinent for (i) amplification of the 
primordial embryonic vascular network as embryogenesis progresses, and in adults (Patan, 2004; 
Li, 2014), as well as (ii) remodeling of uterine spiral arteries into high capacitance and low 
resistance vessels in pregnancy (Cerdeira and Karumanchi, 2012).  
The development of EOPE begins with the pathological upregulation of anti-angiogenic factors, 
e.g. soluble fms-like tyrosine kinase (sFlt1) and soluble endoglin (sEng), with simultaneous 
inhibition of pro-angiogenic factors e.g. vascular endothelial growth factors (VEGFs) and 
placental growth factor (PlGF), thereby promoting an angiogenic imbalance (Burke and 
Karumanchi, 2018). The angiogenic imbalance observed in EOPE results in defective uterine 
spiral artery remodeling, subsequently limiting expansion of the embryonic vasculature and 
thereby giving rise to abnormal placentation (Huppertz, 2018; Staff and Redman, 2018). 
Additionally there is disruption of optimal uteroplacental blood flow and perfusion (Patan, 2004).  
In healthy pregnancies, a delicate balance of reactive oxygen species (ROS) production and 
oxidative stress is maintained to meet the requirements of energy-demanding cells within the 
placenta and the growing fetus (Wang, 2010). However, the abnormal placentation observed in 
EOPE and the effects of maternal factors (e.g. obesity and smoking) in the development of LOPE, 
adversely affect the balance of ROS production and oxidative stress (Wang and Walsh, 1998). 
This ultimately results in the first stage of preeclampsia which is characterized by STB stress 
(Staff and Redman, 2018). STB stress stimulates endothelial cell activation, thereby prompting 
the release of pro-inflammatory molecules into the maternal circulation (Staff and Redman, 
2018). Resultantly, systemic oxidative stress causes widespread inflammation and endothelial 
dysfunction, thereby leading to the second stage of the maternal syndrome of PE, which is 
inclusive of the onset of hypertension and multiple organ failure (Pereira et al., 2015; Rana et al., 
2019). Furthermore, ischemia (Huppertz, 2018), poor fetal vasculature and intra-uterine growth 
restriction occur (Egbor et al., 2006).   
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Figure 1.4. Supplementary illustration of the two stage model of PE development. Abbreviations 
included, (i) early onset of preeclampsia (EOPE); (ii) late onset of preeclampsia (LOPE); (iii) vascular 
endothelial growth factors (VEGF); (iv) placental growth factor (PlGF); (v) soluble fms-like tyrosine 
kinase (sFlt1) and (vi) soluble endoglin (sEng).  
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1.4 Vascular endothelial growth factor (VEGF) family  
1.4.1 Molecular structure and function 
Vascular endothelial growth factors (Figure 1.5) are 40 kDa dimeric glycoproteins (Olsson et al., 
2006) which have a fundamental role in angiogenesis and lymphangiogenesis (Chen and Zheng, 
2014). This family comprises (i) 5 ligands, VEGF-A to VEGF-D and placental growth factor 
(PlGF) (Olofsson et al., 1996; Wang, 2010); (ii) 3 tyrosine kinase receptors, viz., VEGFR-1 -
VEGFR-3; (iii) and 2 non protein kinase co-receptors; (a) neuropilin-1/2 and (b) heparin sulphate 
proteoglycans (Wang, 2010). VEGFs are located on both endothelial and non-endothelial cells 
(Koch et al., 2011).  
 
Figure 1.5. Schematic of vascular endothelial growth factor ligands and respective receptor counterparts. 
Adapted from (Olsson et al., 2006).   
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1.4.1 VEGFR-3  
1.4.2.1 Signaling 
VEGFR-3 is a receptor tyrosine kinase (RTK) with an extracellular component for binding of 
VEGF-C and VEGF-D (Figure 1.5). It comprises 6 immunoglobulin loops with the 5th loop 
cleaved by a disulphide bond (Olsson et al., 2006). VEGF-C/VEGFR-3 signaling exclusively 
facilitates angiogenesis and lymphangiogenesis during embryonic development and in adults 
(Maynard and Karumanchi, 2011). This is achieved in the downstream activation and functioning 
of the phosphatidyl inositol 3’ kinase/protein kinase B (PI3K/Akt) and extracellular signal-
regulated protein kinases 1 and 2 (ERK1/2) pathways (Mäkinen et al., 2001).  VEGFR-3 is 
pertinent for endothelial cell proliferation, migration and remodeling, as well as expansion of 
existing vasculature in angiogenesis (Leach et al., 2002). Stimulation by hypoxia-inducing factors 
(HIFs) (Hong et al., 2004) or an increase in ROS, promotes binding of VEGF-C to VEGFR-3, 
causing VEGFR-3 activation by phosphorylation (Randi et al., 2009). In contrast, VEGFR-3 is 
down-regulated by de-phosphorylation, induced by phospho-tyrosine, a potent modulator of 
VEGFR-3 signaling (Kappert et al., 2005). However, regulatory anomalies may have lethal 
consequences. VEGFR-3 gene polymorphisms in animal models cause intrauterine death 
(Dumont et al., 1998). Furthermore, pathophysiological concentrations of ROS leads to 
endothelial cell damage which sequentially reduces VEGFR-3 bio-availability for angiogenesis 
and lymphangiogenesis (Pereira et al., 2015).  
 
1.4.2.2 VEGFR-3 and HIV infection 
The HIV trans-activator of transcription (Tat) protein is an angiogenic protagonist (Zhang et al., 
2012; Shisadeh et al., 2019), thereby contributing to heightened maternal systemic inflammation 
and endothelial dysfunction (Abbas and Herbein, 2013). In contrast, HAART ameliorates HIV-
induced inflammation and endothelial dysfunction (Naicker et al., 2019).  
However, it has been suggested that HAART may increase oxidative stress (Filardi et al., 2008), 
leading to further endothelial dysfunction, impairment of RTKs (Fiala et al., 2004; Divi et al., 
2010) and exacerbate the pathophysiology of PE (Naicker et al., 2019). This is attributed to 
HAART association with premature deliveries and end organ disease (e.g.: metabolic and 
cardiovascular diseases), both of which are characteristic of PE pregnancies (Townsend et al., 
2010). Therefore it may be concluded that the combined effects of PE, HIV infection and HAART 
10 
 
may exacerbate VEGFR-3 signal dysfunction and subsequently downregulate angiogenesis 
during pregnancy.  
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1.5 Aim  
 
To assess and compare the immuno-expression of VEGFR-3 between conducting (stem) and 
exchange (terminal and intermediate) placental chorionic villi from normotensive, preeclamptic 
and HIV infected women.  
 
1.6 Objectives 
 
 To determine the effect of pregnancy type (normotensive vs. preeclampsia) on the immuno-
expression of VEGFR-3 regardless of HIV status (HIV- vs. HIV+) in the placenta using 
immunocytochemistry with allied morphometric analysis. 
 To determine the effect of HIV status (HIV- vs. HIV+) on the immuno-expression of VEGFR-
3 regardless of pregnancy type (normotensive vs. preeclamptic) in the placenta with allied 
morphometric analysis. 
 To compare and contrast the immuno-expression of VEGFR-3 in the across all study groups 
with the use of immunohistochemistry and allied morphometric analysis. 
 To compare and contrast the immuno-expression of VEGFR-3 between conducting and 
exchange villi across all study groups. 
 To correlate VEGFR-3 immuno-expression with maternal and infant demographic and 
clinical data.  
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          MANUSCRIPT 
 
Original research article entitled: “Morphometric image analysis of vascular endothelial 
growth factor receptor-3 in preeclamptic, HIV infected women” 
 
Chapter two is presented as an original research article which has been submitted to a DoHET 
accredited international journal - European Journal of Obstetrics and Gynecology and 
Reproductive Biology. 
The first author is the author of this Master’s Dissertation (Ms. Saieshni Pillay), contributing to 
the literature and protocol review, experimental procedures and interpretation of the results.  
This research article investigates the immuno-expression of VEGFR-3 in placental villi from 
normotensive, preeclamptic and HIV infected women of African ancestry.  
Citation: Pillay, S. and Naicker, T. (2019). Morphometric image analysis of vascular endothelial 
growth factor receptor-3 in preeclamptic, HIV infected women. Submitted to European Journal 
of Obstetrics and Gynecology and Reproductive Biology, Manuscript ID: EJOGRB-19-20890.  
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Abstract: Objective: To ascertain the expression of vascular 
endothelial growth factor receptor-3 (VEGFR-3) in placental 
conducting and exchange villi from normotensive, preeclamptic (PE) 
and antiretroviral treated pregnant women, using morphometric image 
analysis. 
Study design: This study utilizes retrospectively collected, 
paraffin 
wax-embedded, placental samples (n=90) that were immuno-stained for 
VEGFR-3. The study population consisted of normotensive (n=30) and 
preeclamptic n=60) groups which were further divided on the basis 
of HIV status (negative - and positive +), and early and late onset 
preeclampsia (EOPE and LOPE respectively). The resulting groups 
were as follows; N-(n=15), N+ (n=15), EOPE- (n=15), EOPE+ (n=15), 
LOPE- (n=15) and LOPE+ (n=15). Microscopic examination and 
morphometric image analysis were performed on the immuno-stained 
placental tissue samples. 
Results: Analysis on HIV status did yield a significant difference 
in conducting (p = 0.3015) or exchange (p = 0.4535) villi, 
regardless of pregnancy type. The N vs. PE analysis showed a 
reduced immuno-expression of VEGFR-3 in both conducting (p = 
0.0107) and exchange (p < 0.0001) villi. Results from a multiple 
group comparative analysis of N vs. EOPE vs. LOPE, showed a 
significant difference in the N vs. EOPE analysis regardless of 
villous type. 
Conclusion: The results presented provide compelling evidence that 
HIV 
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infection does not significantly alter angiogenesis in placental 
villi. PE however, has caused angiogenic dysregulation and 
trophoblast pathology was observed. We report a severe 
downregulation of VEGFR-3 in placental villi from EOPE woman, 
regardless of HIV status. Hence we suggest a future investigation 
into EOPE's aetiology and its downstream effects on pregnancy. 
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INTRODUCTION 
Globally, 5-7% of pregnant women in their second or third trimester develop the elusive medical 
disorder known as preeclampsia (PE) [1]. Novel hypertension (≥140/90mmHg) is mandatory for 
diagnosis  and it may or may not be accompanied with proteinuria [2]. Some women however, 
experience a normal and healthy pregnancy, but succumb to PE or eclampsia, prior to or during 
labour, respectively [3]. PE may be classified by gestational age into early onset (EOPE < 34 
weeks) or late onset of PE (LOPE  ≥ 34 weeks) [4].  
The placenta, a highly vascular organ, which constitutes the essence of sustaining and developing 
life in utero, is the causative organ in this multi-faceted disorder [5]. EOPE is a direct result of 
deficient maternal spiral artery remodeling and LOPE is posited to arise from abnormal placental 
growth and size, thereby not conforming to uterine capacity [6]. The lack of myometrial spiral 
artery transformation from low to high capacitance vessels, creates a hypoxic micro-environment 
[7]. This stimulates the release of pro-inflammatory and anti-angiogenic factors into the maternal 
blood circulation [6], which initiates the maternal syndrome [8, 9] and eventuates in intra-uterine 
growth restriction [10]. 
Anti-angiogenic factors (soluble endoglin and soluble fms-like tyrosine kinase) inhibit pro-
angiogenic factors (vascular endothelial growth factors / VEGFs) [11, 12]. VEGFs bind to 
tyrosine kinase receptors (VEGFR1-3) and non-kinase co-receptors, neuropilin 1 and 2, as well 
as heparin sulphate proteoglycans [13]. VEGFR-3 has an indispensable regulatory role in 
angiogenesis and lymphangiogenesis [14]. VEGF-C and VEGFR-3 are cardinal proteins for 
crucial vascular development during early embryonic growth and in adults [15]. The 
establishment and development of the placental vascular and lymphatic network is crucial for 
both the mother and fetus [16]. 
The human immunodeficiency virus (HIV) induces inflammation, thereby altering the existing 
maternal-fetal equilibrium [17]. Both HIV infection and PE account for the high maternal, fetal 
and neonatal morbidity and mortality in South Africa [18]. The HIV accessory protein, trans-
activator of transcription (Tat), is a strong pro-angiogenic factor [19]. In contrast, treatment for 
HIV infection in South Africa includes highly active anti-retroviral therapy (HAART), which is 
anti-angiogenic [20].  
There is a paucity of information on VEGFR-3 expression and function in angiogenesis in the 
duality of preeclamptic and HIV infection. Also, in light of the high prevalence and pervasive 
nature of PE and HIV infection in South Africa, this research project evaluates the immuno-
expression of VEGFR-3 in placental tissue from normotensive, preeclamptic and HIV infected 
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women. This was achieved by comparing the immuno-expression of VEGFR-3 in conducting 
(stem) and exchange (terminal and intermediate) chorionic villi between normotensive and HIV 
associated PE women. 
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MATERIALS AND METHODS 
Ethics 
This research investigation utilized retrospectively collected placental samples of which 
institutional ethics approval was obtained (BCA 338/17).  Post permission to utilize these samples 
(BCA 338/19), immunohistochemistry, brightfield microscopy and morphometric image analysis 
was performed.  
Study population 
Normotensive pregnant and preeclamptic women of African ancestry between 15 and 41 years of 
age were recruited at an antenatal clinic in a large regional hospital in eThekwini, Durban, 
KwaZulu-Natal. A total of 90 women were included and divided into normotensive (N; n=30) 
and preeclamptic (PE; n=60) categories. Further stratification was based on HIV status (negative 
– or positive +) and PE subtypes, such as early or late onset of PE (EOPE; LOPE). The resultant 
groups were N- (n=15), N+ (n=15), EOPE- (n=15), EOPE+ (n=15), LOPE- (n=15) and LOPE+ 
(n=15).  
Preeclampsia diagnosis, as defined by Brown et al., (2018) was applied [2]. Additionally, women 
with an unknown HIV status; have chronic disease(s) (diabetes mellitus type I, II or gestational 
diabetes, chronic hypertension, renal disease, connective tissue disease, systemic erythematosus, 
sickle cell anemia, anti-phospholipid antibody syndrome or thyroid disease); who were on 
medicinal treatment (Aspirin, Warfarin or non-steroidal anti-inflammatory drugs or asthma 
medication); had gestational abnormalities (placental abruption or intra-uterine fetal death) or did 
not deliver via caesarean section, were filtered out during selection. Lastly, maternal and neonatal 
demographic and clinical data were recorded and archived together with consent forms.  
Immunohistochemistry technique  
Following cesarean delivery, a wedge biopsy from the central and peripheral regions of the 
placentae were performed. After overnight fixation in 10% buffered formaldehyde, the samples 
were processed using conventional dehydration, clearing and paraffin wax embedding techniques 
[21]. Thereafter, 3µm sections were cut using a rotary microtome (Leica Biosystems Inc., IL, 
USA) and collected onto X-tra adhesive slides (Leica Biosystems Inc., IL, USA). The primary 
antibody was a VEGFR-3 antibody (clone 54703; catalogue MAB 3491; R&D Systems, USA) 
which was linked to a horseradish peroxidase secondary antibody and finally, visualization was 
mediated by incubation in the 3, 3’-diaminobenzidine (DAB) chromogen using an EnVisionTM 
Flex immunostaining kit (Dako, Denmark). Sections were washed, dehydrated and embedded 
with dibutylpthalate polystyrene xylene.  
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Microscopic examination 
Conducting and exchange villi were viewed using the Zeiss Axio Imager 2 light microscope (Carl 
Zeiss, Germany, Europe) and images were captured at an initial magnification of x20. Two field 
areas of conducting and exchange villi per slide were captured.  
Morphometry 
The Axiovision Image Analysis Software (Version 4.8.3, Carl Zeiss, Germany, Europe) was 
employed for measurement and data analysis of each image.  
Conducting villi 
All regions of interest (ROI; DAB-stained areas of VEGFR-3) of the conducting villi underwent 
a one-phase segmentation using an auto measurement mode. This preceded cleaning, whereby 
any automated labelling of debris, red blood cells etc., were excluded from analysis. The perimeter 
of each villous was framed; thereafter the software generated the percentage of VEGFR-3 within 
the framed area of the villous.  
Exchange villi  
Two-phase segmentation was conducted to determine the percentages of ROI and villous area, 
using an auto measurement mode. Cleaning ensued, followed by framing of the entire field area. 
The average ROI and average villous area percentages were calculated and substituted into the 
equation below to establish the percentage of VEGFR-3 expressed in the total field area of 
exchange villi.  
 
(Average ROI / Total field area of villi) x (100 / 1) = Total field area of VEGFR-3 
immunoreactivity (%) 
 
Statistical analysis  
The output values were input to GraphPad Prism (version 8.3.0; California, USA). Normality 
testing showed that the data was non-parametric. For the comparative analysis across all 6 study 
groups, as well as for the PE subtype analysis (N vs. EOPE vs. LOPE), the one-way ANOVA 
non-parametric Kruskal-Wallis test was employed, followed by Dunn’s Multiple Comparisons 
test. The Mann Whitney test was utilized for pregnancy type (N vs. PE) and HIV status (HIV- vs. 
HIV+) for both villous subtypes. Descriptive statistics have appropriately been presented as 
median and interquartile range for all study group analyses. A p value of p < 0.05 was considered 
statistically significant. 
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RESULTS 
Clinical characteristics 
Demographics and neonatal information is outlined in table 1. Based on HIV status, there was 
significant difference observed in the maternal age (p = 0.001) and birth weight (p < 0.05). 
Notably, the EOPE+ group had the lowest birth weight (p < 0.05), when compared to the other 
groups. The mean gestational age in the EOPE group was statistically lower (p < 0.05), when 
compared to N and LOPE groups.  
VEGR-3 immunolocalization and histopathology 
VEGFR-3 was immuno-expressed within conducting and exchange villi in trophoblast cell types 
(cytotrophoblast and syncytiotrophoblast), endothelial cells, mesenchymal cells and fibroblasts 
within the stroma. Trophoblast cell pathology included cytotrophoblast and syncytial knot 
increase with areas of intra- and extra- villous fibrinoid necrosis.  
Morphometric image analysis  
Conducting villi 
The comparative results of VEGFR-3 immuno-expression across all 6 groups is outlined in table 
2 and in Figure 3.  A significant difference between N- vs. EOPE- (p = 0.0022) and N+ vs. EOPE- 
(p = 0.0212) was noted. VEGFR-3 immuno-expression was significantly reduced (p = 0.0107) in 
the PE (EOPE and LOPE) group, compared to the normotensive group (figure 1a).  
Analysis of the immunostaining pattern of VEGFR-3 differed (p = 0.0159) across the study groups 
(N vs. EOPE vs. LOPE; figure 1b) with an additional difference between N vs. EOPE (p = 0.0121), 
irrespective of HIV status.  
Regardless of pregnancy type, HIV status (figure 1c) did not have a significant (p = 0.3015) effect 
on VEGFR-3 immuno-expression.  
Exchange villi 
The results from comparative analysis of all 6 study groups are shown in table 2 and in Figure 4. 
Similar to the conducting villi, significance is observed across the groups (p = 0.0016) and 
significant differences also exist between N- vs. EOPE+ (p = 0.0092) and N+ vs. EOPE+ (p = 
0.0071).  
Irrespective of HIV status, VEGFR-3 was expressed significantly lower (p < 0.0001) in the PE 
group, when compared with the normotensive group expression (figure 2a). Sub-stratification of 
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the PE groups (figure 2b) showed a decline in VEGFR-3 immuno-expression (p = 0.0002) and 
significant differences between N vs. EOPE (p = 0.0003) and N vs. LOPE (p = 0.0031).  
HIV status analysis (figure 2c) showed that irrespective of pregnancy type, VEGFR-3 immuno-
expression is not significantly (p = 0.4535) effected in exchange villi. 
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COMMENTS 
The primary finding of our investigation was that VEGFR-3 immuno-expression in both 
conducting and exchange chorionic villi was not significantly affected; however it was 
downregulated by HIV status, regardless of pregnancy type. It is important to note that all HIV+ 
women in our study received anti-retroviral therapy (Efavirenz, Nevirapine and HAART), hence, 
the similar VEGFR-3 immuno-expression observed in HIV negative and positive groups. Tat has 
an array of highly specialized functions [22], inclusive of being pro-angiogenic [23]. In a model 
of corneas from HIV infected rabbits, binding of Tat to VEGF co-receptor, heparin sulphate 
glycan, resulted in an up-regulation of angiogenesis [23]. This emanates from the molecular 
similarities between Tat and VEGF, allowing for VEGF mimicry [24]. Specifically, Tat binds to 
the VEGFR-2 receptor and up-regulates angiogenesis via the downstream phosphorylation 
pathways [25]. HIV is also able to elevate VEGF expression via activation of hypoxia inducible 
factor-2α  (HIF-2α) [26]. HIF-2α has an important role in the hypoxic micro-environment of PE 
[27, 28] by regulating VEGF signaling [29, 30]. Hence, we posit that HAART may ameliorate the 
effect of HIV on VEGF expression in the hypoxic state of PE.  
The receipt of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) impairs 
angiogenesis and lymphangiogenesis by disrupting endothelial cell proliferation and migration 
[20, 31, 32]. More specifically, NRTIs affect VEGFR-2 and VEGFR-3 [20]. Moreover, Conroy 
et al. (2017) reported an increase in anti-angiogenic factors with a concomitant decline in VEGF 
rather than VEGFR-3 in HIV+ woman receiving antiretroviral therapy [33].  In our study, there 
was no association between VEGFR-3 and HIV status. Nonetheless, cohorts in Europe [34] and 
the United States [35], and a meta-analysis review by Conde-Agudelo et al. (2008) [36] have 
reported that irrespective of whether or not HIV patients are treated with HAART, PE still 
develops.  
In our study VEGFR-3 immuno-expression was significantly reduced in the conducting and 
exchange chorionic villi (p = 0.0107; p = 0.0016) in PE (EOPE and LOPE groups combined) 
compared to the normotensive group. It is plausible VEGF/VEGFR-3 signaling is dysregulated 
in the anti-angiogenic micro-environment of PE compared to normotensive pregnant women. 
Moreover, in an animal model, VEGFR-3 silencing results in early embryonic loss due to a halt 
in endothelial development [13, 37].  The VEGF-C/VEGFR-3 signaling is vital in lymph-
endothelial migration [38]. VEGF/protein kinase B/endothelial nitric oxide synthase 3 
(VEGF/Akt/eNOS) pathway inhibition prevents VEGF driven nitric oxide secretion thereby 
causing vasoconstriction [39]. Also, VEGFR-3 stimulates the phosphatidylinositol-3-
kinase/protein kinase B (PI3K/Akt) and extracellular signal-regulated protein kinases 1 and 2 
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(Erk1/2) pathways. However, these pathways are dysregulated in PE [40]. Furthermore, 
polymorphisms in the VEGFR-3 tyrosine kinase domains inactivates the kinase enzyme [41].  
In our study the immunostaining pattern of VEGFR-3 differed significantly within conducting (p 
= 0.0121) and exchange villi (p = 0.0003) when analyzing N vs. EOPE groups. In contrast to the 
normotensive pregnant group, the EOPE group is associated with defective placentation with an 
absence of physiological conversion of myometrial spiral arteries [42, 43]. Unexpectedly, we also 
observed a difference in VEGFR-3 immunoreactivity between N vs. LOPE (p = 0.0031) in 
exchange villi. The gestational age of the LOPE group does not reflect the inadequate trophoblast 
cell migration [44].  
In our study, VEGFR-3 was immunolocalized within vascular endothelial cells, trophoblast cells 
and fibroblasts thereby adding to the complex signaling transduction role of VEGFR-3. 
Nonetheless, our findings within non-endothelial cells are corroborated by Orlandini (2006) [45]. 
Recently an absence of lymphatic vessels within the chorionic villi was shown [46]. Pathological 
observations observed in our study such as vasculo-syncytial membrane deficiency may be 
indicative of villous mal-perfusion and villous immaturity [47]. The qualitative increase in 
syncytial knots and cytotrophoblasts in the EOPE group is corroborated by the findings of other 
researchers [48-51]. The cytotrophoblasts are often characteristic of failed cytotrophoblastic 
regression which occurs in immature villi [47].  
There are many risk factors that govern the onset of preeclampsia, one of which is increased fold 
risk in women aged ≥ 35 years [52]. Additionally in our study, the EOPE women delivered lower 
birth weight infants compared to the normotensive and LOPE groups. These results are in 
accordance with current literature on PE pregnancies [53-55] and are independent of HIV status. 
To encapsulate our findings based on the reduced morphometric immuno-expression of VEGFR-
3 within conducting and exchange villi, our findings suggests significant defective VEGF-
C/VEGR-3 signal transduction in PE compared to normotensive pregnant women. However, 
VEGFR-3 immunostaining in both conducting and exchange chorionic villi was not significantly 
affected by HIV status. This similarity may be attributed to the synergistic effect of Tat and 
antiretroviral therapy in HIV infected women.  
These molecular interactions in humans is not well understood, henceforth, research into genetic 
variants of VEGFR-3 in healthy and PE women is essential to understand deregulation of 
angiogenesis and lymphangiogenesis in PE. We also suggest further research into EOPE and 
LOPE to provide affordable early diagnostic testing and therapy in economically deprived 
countries such as Sub-Saharan Africa.  
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Table 1. Maternal and neonatal demographics and clinical data across all 6 study groups.  
Parameters  Normotensive EOPE LOPE 
  HIV- (n=15) HIV+ (n=15) HIV- (n=15) HIV+ (n=15) 
HIV- 
(n=15) 
HIV+ 
(n=15) 
Maternal age (years) 26.5 ± 6.4 27.7 ± 5.5 25.2 ± 6.5 ** 31.8 ± 5.9 ** 24.2 ± 6.4 26.7 ± 4.6 
Gestational age 
(weeks) 
38.5 ± 1.1 38.7 ± 0.7 32.9 ± 2.6 * 33 ± 3.60 * 37.1 ± 6.1 37.4 ± 1.2 
Baby weight 
(g) 
 3346 ± 321 3255 ± 396 2187 ± 799 * 2083 ± 852 * 
3078 ± 457 
* 
2962 ± 277 
* 
Baby sex 
(M:F) 
 14:16 14:16 14:16 12:18 15:15 20:10 
Data reported as mean ± SD and statistical significance considered *p < 0.05 and **p ≤ 0.001.  
 
Table 2. Immuno-expression of placental VEGFR-3 across all 6 study groups. 
Villous type Normotensive EOPE LOPE 
 HIV- (n=15) HIV+ (n=15) HIV- (n=15) HIV+ (n=15) HIV- (n=15) HIV+ (n=15) 
Conducting 
villi 
9.82 
(13.32-5.15)** 
9.00 
(9.00-6.60)* 
6.08 
(6.08-5.25)*, 
** 
8.86 
(11.03-6.17) 
8.71 
(9.43-8.71) 
8.45 
(8.45-8.45) 
Exchange villi 36.48 
(41.19-27.80)** 
35.88 
(37.89-
32.11)** 
30.10 
(34.81-26.52)  
26.23 
(28.98-
19.14)** 
29.94 
(32.67-26.30) 
27.48 
(34.37-27.28) 
Data reported as median and IQR and statistical significance considered *p < 0.05 and **p ≤ 0.001. 
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Figure 1. Histogram illustrating field area percentage of VEGFR-3 immuno-expression within conducting 
villi.  
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Figure 2. Histogram outlining VEGFR-3 immuno-expression (per frame area) of exchange villi.  
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Figure 3. Light micrographs illustrating immuno-expression of VEGFR-3 within conducting villi from a) 
N-; b) N+; c) EOPE-; d) EOPE+; e) LOPE- and f) LOPE+ placenta. Initial Magnification: x20. 
Morphological observations denoted: FB = Fibroblast; S = Syncytium; EC = Endothelial cell; FN = 
Fibrinoid necrosis; SK = Syncytial knot; CTB = Cytotrophoblast. 
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Figure 4. Light micrographs illustrating immuno-expression of VEGFR-3 within exchange villi from a) N-
; b) N+; c) EOPE-; d) EOPE+; e) LOPE- and f) LOPE+ placenta. Initial Magnification: x20. Morphological 
observations denoted: FN = Fibrinoid necrosis; SK = Syncytial knot; CTB = Cytotrophoblast. 
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SYNTHESIS, CONCLUSION AND FUTURE PERSPECTIVES 
 
3.1 Synthesis 
 
South Africa is a low-middle income country with 13.5% of its overall population being HIV+; 
moreover more than 1/5 of women in their reproductive age are infected with the virus (StatsSA, 
2019). Since 2016, mother to child transmission with ARV usage has plateaued at 0.71% 
(AVERT, 2018). Pregnancies are further complicated by HDPs, which are responsible for 14% 
of maternal mortality (NCCEMD, 2018). Of these occurrences, PE is the most prominent 
(Moodley et al., 2019).  
Due to PE and HIV infection being the leading causes of maternal and fetal morbidity and 
mortality in South Africa (NCCEMD, 2018), these conditions are currently under intense scrutiny. 
It has since been established that a disproportion of angiogenic factors is induced in both 
conditions (Karumanchi and Granger, 2016) and the VEGF family has been observed as being 
targets of HIV accessory protein, Tat (Levine et al., 2004).  
In light of the high incidence of HIV infection and preeclampsia in South Africa, it is urgent that 
the duality of these co-morbidities on VEGF/VEGFR-3 signaling during angiogenesis and 
lymphangiogenesis be investigated.  
This study demonstrates a reduced placental VEGFR-3 immuno-expression in the HIV+ groups. 
Although not significant, it is plausible that the HIV Tat protein stimulates endothelial cells to 
activate angiogenesis (Arasteh and Hannah, 2000). The binding region of the Tat protein is 
arginine- and lysine-rich, similar to that of VEGFs (Albini et al., 1996). This mimicry allows Tat 
to bind to the VEGFR co-receptor, heparin sulphate glycoprotein (Albini et al., 1996). 
Furthermore, endothelial cell transmembrane integrin proteins (potent modulators of VEGFR-3) 
are targeted by Tat to upregulate downstream signaling within the PI3K/Akt pathway for 
activation of angiogenesis (D'Oria et al., 2017). Also, HIF-2ɑ upregulates VEGF (i) during 
embryonic development; (ii) for tissue growth and (iii) in oxygen poor micro-environments 
induced by pregnancy complications (PE) and viral infections (HIV) (Korgaonkar et al., 2008). 
Subsequently, as a compensatory mechanism VEGF/VEGFR signaling stimulates angiogenesis 
(Verma et al., 2018).  
However, it is notable that all HIV+ women in our investigation were administered ARVs 
(combined HAART, Efavirenz and Nevirapine) which inhibit (although not 100% effective) HIV 
viral replication and upregulation of angiogenesis (Song et al., 2018). Nucleoside reverse 
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transcriptase inhibitors (NRTIs) and non-NRTIs (Efavirenz and Nevirapine) are HIV viral 
suppressors and are anti-angiogenic/anti-lymphangiogenic (McNeil et al., 2017). Since VEGFR-
3 is a critical regulator of both processes, binding with VEGF-C is blocked (Song et al., 2018). 
This is substantiated by the results observed in our study where HIV status did not significantly 
affect VEGFR-3 immunostaining in both conducting and exchange villi. Henceforth, based on 
the mechanisms of ARV’s and the results from our study it may be posited that while ARVs do 
not completely inhibit viral action, they are able to sufficiently prevent over stimulation of 
VEGFR-3 activation-induced angiogenesis.  
This study has observed low VEGFR-3 immuno-expression in conducting (p = 0.0107) and 
exchange (p = 0.0016) villi from the preeclamptic pregnancies. In PE, the overproduction of 
placental ROS creates an ischemic micro-environment (Pereira et al., 2015).  Maynard et al., 
(2003) have reported that consequent to a high ROS concentration, anti-angiogenic factors (e.g. 
sFlt-1) are released into the maternal circulation, which cause systemic endothelial cell damage 
and dysfunction (Maynard et al., 2003). Furthermore, targeted gene inactivation or inhibition of 
VEGFR-3 result in blood vessel anomalies (Ferrara, 2001). Karkkainen et al., (2001) have 
observed RTK inactivity in mouse models carrying VEGFR-3 polymorphisms (Karkkainen et al., 
2001). Damages to the molecular structure of VEGFR-3 would reduce its expression within 
endothelial cells where it would affect placental vascular formation and development (Chen and 
Zheng, 2014). The results of a significant downregulation of VEGFR-3 in both the conducting 
and exchange villi from the preeclamptic women in our study possibly emanates from 
dysregulation of VEGF-C/VEGFR-3 signaling.  
It is important to note that some of the women included in this study were preeclamptic and HIV+, 
thus the dual nature of the opposing inflammatory conditions may further dysregulate VEGF-
C/VEGFR-3 signaling. Notably, as aforementioned, PE and ARVs are anti-angiogenic whilst the 
HIV Tat protein has a pro-angiogenic effect. The combined effects of PE, HIV infection and 
ARVs may present severe consequences. Bahram and Claesson-Welsh (2010) report that 
VEGFR-3 degradation renders the RTK inactive (Bahram and Claesson-Welsh, 2010). Loss of 
activation of PI3K/Akt and ERK1/2 pathways in the duality of PE and HIV (D'Oria et al., 2017; 
Song et al., 2018) lead to under-developed placental vasculature.  
Interestingly, a comparison of the immuno-expression of VEGFR-3 across the normotensive, 
EOPE and LOPE groups in our study, showed that the most significant multiple group comparison 
was between normotensive and EOPE (conducting villi: p = 0.0121; exchange villi: p = 0.0003). 
EOPE is a direct result of defective placentation and superimposed defective angiogenesis (Burke 
and Karumanchi, 2018). It is plausible that the PI3K/Akt and ERK1/2 pathways are dysregulated 
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in the duality of PE and HIV infection. Chen and Zheng (2014) confirm that activation of these 
pathways by VEGFs is pertinent for stimulation of angiogenesis and sequentially, endothelial cell 
proliferation, migration and vessel formation (Chen and Zheng, 2014). Several studies 
corroborate reduced angiogenesis by VEGF activation as reported in our study (Zheng et al., 
2008; Feng et al., 2012). Furthermore, heightened ROS production and systemic inflammation 
reduce VEGFR-3 bio-availability (Wang, 2010). This coincides with abnormal placentation as 
observed in the development of EOPE and substantiates the reduced VEGFR-3 immuno-
expression in placental villous samples from women with EOPE.  
Additionally, EOPE women included in our study were associated with early delivery and low 
birth weight (p < 0.05), compared to the normotensive and LOPE groups. Furthermore, these 
findings were independent of HIV status. Due to reduced VEGFR-3 immuno-expression observed 
in the EOPE groups, it is not surprising that the reduced angiogenesis was associated with 
defective placental and fetal vasculature. Furthermore, women aged ≥ 35 years have a 
predisposition to PE development (Bartsch et al., 2016). Notably, there was significance 
difference (p ≤ 0.001) in maternal age between the normotensive and the EOPE groups.  
This research presents a novel finding of significantly reduced VEGFR-3 immunostaining in 
LOPE exchange villi (p = 0.0031) when compared to the normotensive group. This is unexpected 
as LOPE is not a result of angiogenic imbalance and abnormal placentation, as its onset occurs 
much later in pregnancy, near term. LOPE is primarily caused by factors that are extrinsic to the 
placenta (Staff and Redman, 2018). Such factors include maternal smoking and obesity (Wang 
and Walsh, 1998). However, keeping in mind that 67% of women in our study population were 
HIV+ and receiving ARVs, it is plausible that the introduction of antiretroviral therapy caused 
down-regulation of VEGFR-3 immuno-expression. ARV inhibition of angiogenesis and 
lymphangiogenesis is corroborated by several researchers (Song et al., 2018; Naicker et al., 2019; 
Monini et al., 2003).  
Prominent pathological observations in our study included trophoblast anomalies such as, 
increased appearance of syncytial knots and cytotrophoblasts, vasculo-syncytial membrane 
deficiencies, as well as fibrinoid necrosis. These findings are substantiated by several studies on 
placental pathology in PE complicated pregnancies (Hansen et al., 2000; Sebire et al., 2005; 
Heazell et al., 2007; Huppertz, 2011).  
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3.2 Conclusion and future prospectives 
 
This study is the first to observe the immuno-expression of VEGFR-3 in the placenta of 
preeclamptic and HIV+ women receiving ARV treatment. We find that HIV infection does not 
have a significant effect on VEGFR-3 immuno-expression and angiogenesis, with or without the 
presence of additional PE. However, we have posited that combined ARV therapy may shadow 
the true effect of HIV infection. These novel findings specifically infer serious dysregulation in 
EOPE women, regardless of HIV infection. Furthermore, our findings draw attention to the need 
to re-evaluate the effects of ARV therapy on angiogenic dysregulation in PE concomitant HIV 
infection. Further large scale studies to confirm the biomarker values of VEGFR-3 is important 
to develop therapeutic interventions and specialized care for affected women. We advocate the 
establishment of economically viable strategies for the early detection of PE, particularly in 
financially constrained countries.  
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